Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Laparoscopic bariatric surgery is safe during phase 2–3 of COVID-19 pandemic in Italy: A multicenter, prospective, observational study

Gianfranco Silecchia, Cristian E. Boru, Giuseppe M. Marinari, Paolo Gentileschi, Mario Morino, Stefano Olmi, Mirto Foletto, Paolo Bernante, Riccardo Morganti, Carlo Tascini, Marco Anselmino, Emanuela Biancardi, Michela Campanelli, Luigi Fiorello, Rudj Mancini, Alberto Oldani, Matteo Rottoli, Antonio Salzano, Manuela Trotta, and the cooperative RESTART group

Article history:
Received 11 May 2021
Received in revised form 1 June 2021
Accepted 9 June 2021
Available online 13 June 2021

ABSTRACT

Background: Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS’ resumption. A new, more severe COVID-19 surge, the “second wave”, started on October 2020 (phase 3).

Aim: The primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2–3; secondary end points were readmission and reoperation rates.
Methods: Study design prospective, multicenter, observational.
Setting: Eight Italian high-volume bariatric centers. All patients undergoing BMS from July 2020 through January 2021 were enrolled according to the following criteria: no Sars-Cov-2 infection; primary procedures; no concomitant procedure; age > 18 < 60 years; compensated comorbidities; informed consent including COVID-19 addendum; adherence to specific admission, in-hospital and follow-up protocols. Data were collected in a prospective database. Patients undergone BMS during July-December 2019 were considered a control group.

Results: 1258 patients were enrolled and compared with 1451 operated on in 2019, with no differences for demographics, complications, readmission, and reintervention rates. Eight patients (0.6%) tested positive for Sars-Cov-2 infection after discharge, as well as and 15 healthcare professionals, with no related complications or mortality.

Conclusions: Introduction of strict COVID-19 protocols concerning the protection of patients and health-care professionals guaranteed a safe resumption of elective BMS in Italy. The safety profile was, also, maintained during the second wave of outbreak, thus allowing access to a cure for the obese population.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

A temporary suspension of the bariatric surgical programs all over the world was one of the immediate consequences of the Sars-Cov-2 virus generated pandemics, especially in Italy, the first European country seriously affected by the Coronavirus disease 2019 (COVID-19). The first indigenous person-to-person Sars-Cov-2 transmission in Italy was reported on February 2nd, and by March 3rd, 2020 all elective bariatric and metabolic surgical procedures (BMS) were suspended. Due to the rapid spread and the aggressive nature of the virus it was considered safer to postpone all elective surgical procedures, in order to preserve the resources and significantly curb the viral transmission/circulation [1]. BMS is a highly demanding resource field, both human and logistics, involving activities at high risk of transmission, such as airway management [2]. One year later more than 3,900,000 coronavirus cases, and over 127,000 related deaths, have been registered in Italy (http://www.salute.gov.it/portale/home.html).

Obesity represents a chronic disease, a pro-coagulant and pro-inflammatory state which may increase the risk of thrombosis and exaggerated cytokines and oxidative stress response [3]. The role of obesity during the outbreak has not been ignored, being independently associated with increased risk for intensive care unit (ICU) admission and intubation [4]. Obesity, an already recognized pandemic itself, being associated with a higher risk of infectious diseases, in particular of the respiratory tract [5,6], plays an important role in a more serious outcomes from Sars-Cov-2 infection, with a higher risk of developing severe pneumonia, especially in men [7,8]. Furthermore, obesity is associated with, and responsible for, comorbid conditions that may represent an increased risk of unfavorable Sars-CoV-2 infection outcomes [9,10].

So far, BMS represents the most effective treatment in obtaining a long-term meaningful weight loss [11], and resolution of related comorbidities, including respiratory disorders [12–14]. Recent findings suggests that BMS is associated with a lower rate of mortality and hospital admission in patients with obesity who, afterwards become infected with SARS-CoV-2 [2,15]. In May 2020, a slight decrease of the pandemic was observed in Italy and a gradual and progressive decrease of the lockdown restrictions was started (phase 2), when the virus was supposed to be under control and protocols and regulations were guiding National Healthcare Sys-

Table 1 – Participating centers to the study and regional location in Italy.

| Center | Italian Region |
|--------|----------------|
| Division of General Surgery and Bariatric Center of Excellence IFSO-EC, Department of Medico-Surgical Sciences and Biotecnologies, University “La Sapienza” of Rome | Central |
| Bariatric Unit, Humanitas Clinical and Research Hospital, IRCCS Rozzano, Milan | North |
| Department of Bariatric and Metabolic Surgery, San Carlo of Nancy Hospital & “Tor Vergata” University of Rome | Central |
| General Surgery, Department of Surgical Sciences, University of Turin | North |
| Department of General and Oncological Surgery, Center of Bariatric Surgery, Policlinico San Marco di Zingonia, Bergamo | North |
| Bariatric Surgery Unit, Azienda Ospedaliera of University of Padova | North |
| Bariatric & Metabolic Surgery Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria Policlinico di Sant’Orsola Bologna | Central |
| Bariatric and Metabolic Surgery Unit, Azienda Ospedaliera at University of Pisa | Central Backspace |
In a previous paper we reported the results of a multicenter retrospective study, evaluating the risk of infection during 840 BMS procedures, performed without specific precautions during January-February 2020 (when the circulation of the virus has been subsequently demonstrated) [16]. We found five infections (5.9 cases of 1000 inhabitants), two had mild symptoms requiring home treatment, and three were hospitalized for fever and dyspnea; none died, all made a full recovery. In the same group of patients, the rate of postoperative complications was similar in comparison to the rate recorded in patients undergoing BMS in the eight centers during the same period of 2019: 14 severe complications (Clavien-Dindo III-IV grade classification) [17] vs. 12 grade III in 2019, showing a similar outcome ($p = 0.701685$). With a view to a progressive and prudent restart of elective BMS, while fully respecting patient safety, the need for the curative surgery, and the prioritization criteria, an expert panel of bariatric surgeons and infectious disease specialists agreed on the criteria for patient selection, protocols, both in and out of hospital, to minimize the risk of Sars-Cov-2 infection in phase.

Unfortunately, in October 2020 a third phase of the pandemic started, with a new wave of infection spreading in Europe and Italy, forcing the selective closure of elective bariatric activity, for a temporary period (2–4 weeks) based on epidemiological data and the government’s strategy.

**Primary end point**: Mortality and morbidity over 30 postoperative days (POD) from Sars-Cov-2 infection, in order to check the effectiveness of the hospitals’ protocols in minimizing the risk of postoperative infection after elective BMS.

**Secondary end points**: perioperative readmission rate (30 days), reoperations for any reason, and infection rate among healthcare professionals.

### 2. Methods

This was a multicenter, prospective, observational study carried out in eight Italian, SSN’s high-volume bariatric centers (Table 1). The study was conducted in accordance with the principles of Good Clinical Practice, as well as with the study’s protocol registered within clinicaltrials.gov (NCT04480034; Unique Protocol ID: 0008758/27.05.2020). The study was approved by the Local Ethical Committee (Lazio 2 Rome, Protocol no. 0104988/2020 of 26/06/2020) as well as by the local Boards and Ethical Committee of each participating center. The protocol respects the STROBE statement and checklist [18] and did not change during the study’s period: July 2020 – January 2021. Candidates were enrolled according to the following criteria: no previous Sars-Cov-2 infection; primary bariatric surgery; no concomitant procedure, excluding hiatal hernia repair; no previous major abdominal surgery; >18 < 60 years old; compensated comorbidities; BMI < 60 kg/m$^2$; laparoscopic standard bariatric procedure endorsed by Italian Society for Obesity Surgery (SICOB); estimated procedure duration < 120 min; official SICOB’s surgical informed consent given, including COVID-19 and participation to the study addendums.

All the participating centers followed the standard recruitment, ambulatory (including telemedicine) and in-hospital, OR and after discharge protocols, updated to the national and regional guidelines [19,20,21]. Patients with obesity were considered eligible for surgery, maximizing equity of access and minimizing the harm from delayed access [22,23].

### 3. Hospital admission, in-hospital and OR management and after discharge protocols

#### 3.1. Hospital admission protocol

The patient was checked 2–3 days before admission by telephone interview (Table 2), to rule out fever (threshold value > 37.5°C/99.5°F), respiratory symptoms, vomiting, diarrhea, conjunctivitis, changes in smell or taste, osteoarticular pain, excessive fatigue, or contact in the previous two weeks with a confirmed case (clinical diagnosis - positive swab for Sars-Cov-2); a PCR/antigenic swab Sars-Cov-2 test was performed in all enrolled patients 24–48 h prior to hospital admission. The medical staff repeated the above interview on admission and the patient received and signed a specific consent.

| Table 2 – Patients’ COVID-19 questionnaire over the phone: preoperative (2 days before hospital admission) and postoperative (7th & 14th postoperative day and directly at the outpatient visit on the 30th). |
|---|
| **Patients preoperative and postoperative COVID-19 survey** |
| **Preoperative (2 days before admission, over the phone)** |
| During the 30 days prior to the surgery did you travel abroad or outside your region or were you exposed to people that travelled abroad/outside your region? |
| During the 30 days prior to the surgery were you exposed to people who were diagnosed with COVID-19? Yes/ no. How, how long? |
| During the 30 days prior to the surgery did you experience any symptoms concerning of COVID-19, including: respiratory symptoms, vomiting, diarrhea, conjunctivitis, changes in smell or taste, osteoarticular pain, excessive fatigue? Yes/ no. Which? |
| **Postoperative (over the phone on the 7th & 14th postoperative day and direct on the 30th)** |
| During the 7/14/30 days after the surgery you experience any symptoms concerning of COVID-19, including: respiratory symptoms, vomiting, diarrhea, conjunctivitis, changes in smell or taste, osteoarticular pain, excessive fatigue? Yes/ no. Which? |
| During the 7/14/30 days after the surgery were you exposed to people who were diagnosed with COVID-19? Yes/ no. How? |
| During the 7/14/30 days after the surgery you diagnosed or hospitalized with COVID-19? Yes/ no. How? |
COVID-19 consent, together with specific bariatric operation consent and participation in the study. Further screening before admission consisted of a chest X-ray or CT-scan, and blood analysis.

3.2. Operating Room (OR) protocol

Standard personal protective equipment (PPE) plus N95 masks for the surgeons, while for the anesthesiologists and nurses who managed the airways and gastric bougie positioning, the N99 mask was recommended, using face shields, single-use waterproof gowns, and double gloves; restricted access in the OR; expert surgeons and anesthesiologists performed the procedures to minimize the OR occupation time; a smoke evacuator system was employed to avoid air-borne contamination; in the alternative, a filter was connected to the exsufflation system. A negative pressure in the OR was not mandatory, but it was crucial to allow enough time between consecutive cases for a change of air in the room. When the OR was used for intensive care during phase 1 of the pandemic, proper sanitization was a necessity.

3.3. Management of in-hospital patients

No COVID-19 hospital/section was used for elective BMS; standard PPE for staff was mandatory; social distancing had to be respected even in the case of post-surgical mobilization; patients had to wear a surgical mask at all times. Each patient received a single room, however in the case of a larger ward being used, he/she was assigned a suitable space in compliance with social distancing regulations. ERAS (Enhanced Recovery After Surgery) protocol was used whenever possible. Where >48 h hospitalization was needed, Sars-Cov-2 tests were performed on discharge. No visitors were allowed. All caregivers were required to wear masks at all times. Policies were implemented to transfer COVID-19 patients to other facilities.

3.4. After discharge

In the case of intra-hospital contact with Sars-Cov-2 positive patient or healthcare professional, 14 days self-quarantine after discharge was mandatory. After 7 and 14 POD patients received a follow-up phone call, with specific questions about COVID-19 (Table 2) to quantify the number of symptomatic patients, who were tested and diagnosed with COVID-19. First outpatient visit was scheduled for the 30th POD, when the same data acquiring protocol was used.

3.5. Patients and public involvement

Patients were not involved in designing the research questions, outcome measures, or interpretation or writing up of results of this study. Patients’ representatives, in our ethics committee, were asked for comments on general comprehensibility. The patients’ representatives of each participating hospital were informed about the study and its start. Results will be presented to patients and public as part of regular information events.

| Table 3 – Demographics of the study participants; bariatric metabolic operation types and numbers; number of obese patients presenting comorbidities. Participants were enrolled July 15, 2020–January 31, 2021 (study group); control group was consisted of patients operated between July 1 2019–December 31, 2019. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| N 1451          | 1258            | p-value         |
| Age (y)         | 42.1 (11)       | 42.7 (10.5)     | 0.174           |
| Height (m)      | 1.66 (0.09)     | 1.66 (0.09)     | 0.575           |
| Weight (Kg)     | 120.9 (20.4)    | 121.2 (20.1)    | 0.738           |
| BMI (Kg/m²)     | 43.6 (5.3)      | 43.6 (5.4)      | 0.910           |
| Operation time (min) | 60.3 (19.4) | 58.9 (22)      | 0.160           |
| Gender          |                |                |                 |
| Female          | 1012 (69.7)     | 889 (70.7)      | 0.599           |
| Male            | 439 (30.3)      | 369 (29.3)      | 0.599           |
| Operation type  |                |                |                 |
| Sleeve gastrectomy | 1225 (84.4) | 1109 (88.2)     | 0.005           |
| R-en-Y gastric bypass | 166 (11.4) | 97 (7.7)       | 0.001           |
| OAGB/MGB         | 60 (4.1)        | 52 (4.1)        | 0.923           |
| Comorbidity      | 867 (59.7)      | 711 (56.5)      | 0.005           |

Information on patient demographics including age, sex, Body Mass Index (BMI) and co-morbidities, operation details such as the type and duration of BMS, were collected. Perioperative outcomes including length of stay, ICU admissions, Emergency Department (ED) visits, re-admissions, re-operation, complications, and mortality within 30 days were also analyzed. For the 2020 cohort, pre- and post-operative Sars-Cov-2 PCR testing results and the development of any related symptoms were included.

The Rt index, or the R number, describes the average number of secondary infections generated by an infected person on a certain date. It was used by the Italian Government to monitor the progression of the epidemic. A value of Rt above the threshold (Rt 1), even in presence of a low number of cases, was interpreted as an alarming sign of the escalating trend of the epidemic.

All data were collected from a prospectively maintained, online registry. In this prospective observational longitudinal study, categorical data were described by absolute and relative frequency, continuous data by mean, standard deviation and range. To compare qualitative and quantitative clinical/anthropometric factors between the two groups of study (2019; 2020–21) z-test for two proportions and t-test (two-tailed) were used, respectively. Significance was fixed at 0.05 and all analyses were carried out by SPSS v.27 software.

4. Results

Elective laparoscopic BMS in the eight participating centers, was made up on a cohort of 1258 patients, vs. 1451 patients operated during June - December 2019, with no difference in demographics, complications, readmission, and reintervention rates (Table 3). Follow-up was completed in 100% of the cases for each center. No conversion to open surgery was encountered, with only one perioperative death registered, due to pulmonary thromboembolism (0.07%) in the study.
procedure (88% group. Sleeve gastrectomy (LSG) was the most common procedure, more LSGs were performed in 2020, when statistically compared. All related comorbidities were registered, hypertension, obstructive sleep apnea and diabetes being most frequent, and were more associated in the control group, without showing any significant difference (Table 4).

The majority of complications encountered were leaks (5 in the study group vs. 8), bleeding (12 vs. 19), anastomotic bleeding (1 vs. 2, p < 0.001). All complications were successfully treated, with no further complications.

5. Discussion

This is the first multicenter, prospective, observational study on the safety and feasibility of BMS during the COVID-19 Italian epidemic, performed during two distinct periods: the so-called phase 2, low incidence phase (June-September 2020), and phase 3 or second wave (October 2020 – January 2021), the latter still ongoing as we proffer this manuscript. As a matter of fact, during the second Italian wave 1,822,841 positive cases were registered vs. 236,134 registered during the first wave of the pandemic. Among over 100,000 Italian vic-

### Table 4 – Comorbidities encountered in both groups of morbid obese patients that undergone bariatric/metabolic surgery during the study period (2020–2021) and control period (2019).

| Comorbidity                          | 2019 (n: 1451) | 2020–21 (n: 1258) |
|-------------------------------------|---------------|-------------------|
| Hypertension                        | 386 (26-6)    | 351 (27-9)        |
| OSAS                                | 271 (18-7)    | 225 (17-9)        |
| Diabetes                            | 219 (15-1)    | 172 (13-7)        |
| Hyptothyroidism                     | 32 (2-1)      | 34 (2-7)          |
| Venous insufficiency                | 8 (0-5)       | 9 (0-7)           |
| Hypertriglyceridemia/Hypercholesterolemia | 218 (15)  | 157 (12-5)        |
| GERD                                | 49 (3-4)      | 47 (3-7)          |
| Hiatal hernia                       | 19 (1-3)      | 19 (1-5)          |
| Arthropathy                         | 131 (9)       | 100 (7-9)         |
| IGT                                 | 37 (2-5)      | 32 (2-5)          |
| Cholelithiasis                      | 0 (0)         | 4 (0-3)           |
| Hepatic steatosis                   | 51 (3-5)      | 35 (2-8)          |
| Others                              | 87 (0-6)      | 68 (5-4)          |

### Table 5 – Prevalence (expressed as number of Sars-Cov-2 positive cases at the given time point/1000 people) and Regional Rt values (the average number of secondary infections generated by an infected person on a certain date) for the study period. Data was extrapolated according to the date of study initiation (July 1st, 2020) and end (Jan 31st, 2021) according to the participants’ origin (province or region). Rt data was only available according to region for the specific time points [24,25].

| Province         | Regional Rt1, 2 | Prevalence (n/1000)3 | Overall population3 |
|------------------|-----------------|----------------------|---------------------|
|                  | 29th Jun-5th July 2020 | 25th Jan-31st Jan 2021 | 1st July 2020 | 31st Jan 2021 |
| Torino           | 1.06 (CI 0.87-1.31) | 0.82 (CI 0.72-0.99) | 7.07 | 66.49 | 2,247,780 |
| Rome             | 1.07 (CI 0.45-2.05) | 0.82 (CI 0.7-1.06)  | 1.47 | 46.09 | 3,997,465 |
| Pisa             | 1.12 (CI 0.35-2.9)  | 1.02 (CI 0.87-1.31) | 2.26 | 54.60 | 411,190  |
| Padova           | 1.2 (CI 0.39-2.28)  | 0.65 (CI 0.58-0.8)  | 4.29 | 73.72 | 921,361  |
| Bergamo          | 0.92 (CI 0.66-1.26) | 0.9 (CI 0.77-1.03) | 13.23 | 37.2 | 1,088,284 |
| Milano           | 0.92 (CI 0.66-1.26) | 0.9 (CI 0.77-1.03) | 8.03 | 74.09 | 3,038,420 |
| Bologna          | 1.2 (CI 0.76-1.88)  | 0.84 (CI: 0.72-1.06)| 5.36 | 50.1 | 976,243  |
| Mean             |                  |                      | 5.96 | 57.47 | 12,680,743 |
| National Mean    | 18th Jun 2020-1st Jul 2020 | Approx. 0.84 | 20th Jan-2nd Feb 2021 | 0.95 (CI 0.86-1.06)6 | 3.97 | 42.08 | 59,433,744 |

...
times of COVID-19, obesity was identified as a risk factor in 10–8%, for both genders [26]. Nevertheless, resuming elective BMS was mandatory given the uncertainty regarding the effects and duration of the outbreak, combined with the progressive nature of obesity and related conditions, while delaying BMS could have increased the risk of morbidity and mortality in surgical candidates [23]. The risk of harm during the surgical process, however, is different for each patient, depending on the type and severity of disease and their suitability for BMS. Patients undergoing BMS are not at increased risk of Sars-Cov-2 infection compared to the general surgery population. The 30-day morbidity and mortality following BMS performed during the phase 2–3, with appropriate perioperative protocols, appeared to be similar to the pre-pandemic levels, as shown in a recent retrospective, observational, international cohort study on 2116 adult patients who underwent primary BMS in 133 hospitals from 35 countries [27]. There were ten (0.5%) symptomatic cases diagnosed after BMS, similar to the one reported in our study, both before and during the pandemic.

Patients who had BMS would have a decrease in their fat stores, improvement of their comorbidities, and hence make them less susceptible to severe outcomes if they catch Sars-Cov-2 infection [28]. A nationwide French study was conducted on 8286 individuals with a previous diagnosis of obesity, admitted for COVID-19 between January 1st and May 15th, 2020; 541 patients had a history of BMS [15]. The need for invasive mechanical ventilation and death occurred in 7% and 3.5% of the BMS group versus 15% and 14.2% of the control group, respectively, so BMS is independently associated with a reduced risk of death and invasive mechanical ventilation.

The restart of elective BMS, performed under strict, updated in-hospital and ambulatory regulations, based on national and international guidelines [19–23,29] was analyzed for the first 30 POD Sars-Cov-2 incidence, its mortality, and complications, as well as the perioperative readmission or reoperation rate. Only 8 patients (0.6%) tested positive for Sars-Cov-2 postoperatively, and diagnosis was established after hospital discharge. The 0.6% rate Sars-Cov-2 infection at 30 days seems to be related to the family/environment link, without excluding the possibility that infections occurred during the hospitalization, and patients became positive or symptomatic after discharge, at home. Five of these patients were located in North Italy, the area most affected during this pandemic, while the rest are located in Rome metropolitan area, highly affected, as well, during the second wave. No specific conditions were registered for these 8 patients, nor for their morbid obesity or associated conditions. No concomitant patients and health professionals were recorded or could be demonstrated. The 15 healthcare professionals infected were involved in a greater variety of in-hospital and ambulatory activities, not restricted to the bariatric area, and we could not find a direct connection between them and the patients who tested positive after hospital discharge. We consider that infections among patients or personnel were completely unrelated.

There was no difference for bariatric surgery’s complications, perioperative readmission or reoperation rate between the 2 analyzed periods, except for anastomotic bleedings and postoperative pulmonary embolism (only one event registered in 2020). The lower number of procedures performed in 2020 in the eight centers (13 5% reduction compared to 2019, without reaching a significant cutoff) is easy to comprehend: all the involved centers faced serious difficulties in this period, determined by the reduction in available ORs, allocated hospital admissions, more complicated in-hospital patients management. Additionally, all centers faced tempo-

| Table 6 – Complications by Clavien-Dindo (CD) classification after bariatric/metabolic procedures; Sars-Cov-2 tested positive patients during the first 30 postoperative days; all adverse events from time of surgery up to 30 POD for all patients, both in the study group (operated between July 2020–January 2021) and control group (operated between July 2019–December 2019). |
|---------------------------------|---------------------------------|---------------------------------|
| Complication by CD classification system grade | 2019 (n 1451) | 2020 (n 1258) | p-value |
| CD grade I | 21 (1 45) | 8 (0 64) | 0.064 |
| CD grade II | 27 (1 86) | 17 (1 35) | 0.371 |
| CD grade IIIA | 3 (0 21) | 1 (0 079) | 0.702 |
| CD grade IIIB | 11 (0 76) | 16 (1 27) | 0.255 |
| CD grade IVA | 1 (0 069) | 1 (0 079) | 0.359 |
| CD grade IVB | 0 (0) | 0 (0) | 1 |
| CD grade V | 0 (0) | 1 (0 079) | 0.948 |
| Total | 63 (4 34) | 44 (3 50) | 0.307 |
| COVID-19 Sars-Cov-2 positive | Non tested | 8 (0 6) | 0.01 |
| Specific complication | | | |
| Leak (sleeve) | 8 (0 6) | 5 (0 4) | 0.646 |
| Bleeding | 22 (1 7) | 11 (1) | 0.163 |
| Anastomotic bleeding | 2 (0 14) | 1 (0 07) | <0.001 |
| Wound infection | 6 (0 4) | 6 (0 4) | 0.760 |
| Deep vein thrombosis | 1 (0 07) | 1 (0 07) | 0.817 |
| Pulmonary embolism | 0 (0) | 1 (0 07) | 0.004 |
| Respiratory | 3 (0 2) | 4 (0 3) | 0.893 |
| Abscess | 1 (0 07) | 2 (0 1) | 0.692 |
| Occlusion | 1 (0 07) | 2 (0 1) | 0.692 |
| Others | 10 (1 1) | 6 (0 5) | 0.130 |
The metadata will be available through the dedicated online platform https://test-3mstudy.pantheonsite.io/user/login and will be available for secondary analysis once the study has completed.

Role of the funding source

The funder of the study had no role or support in the study design, data collection, data analysis, data interpretation, or writing of the report.

Acknowledgments

The study was partially funded, unconditionally, by a research grant from Johnson & Johnson Medical, Ethicon Division, that was used exclusively for database creation and maintenance, data collecting. This funding source had no role or support in the study design, data collection, data analysis, data interpretation, or writing of the report.

We would like to thank all the staff supporting study delivery at participating sites and all participants for their ongoing commitment and contributions to this study. We also thank Alexandru Berendei, Bucharest, Romania, IT specialist, developer & manager of the dedicated online platform and to Dr. Alberto Di Biasio, data manager.

References

[1] Lazaridis II, Kraljevic M, Schneider R, et al. The Impact of the COVID-19 Pandemic on Bariatric Surgery: Results from a Worldwide Survey. Obes Surg 2020;30(11):4428–36. https://doi.org/10.1007/s11695-020-04830-8. Collaborators, Epub 2020 Jul 11.
[2] Brindle ME, Gawande A. Managing COVID-19 in Surgical Systems. Ann Surg 2020;272(1):e1–2. https://doi.org/10.1097/SLA.0000000000003923
[3] Aminian A, Tu C. Association of Bariatric Surgery with Clinical Outcomes of SARS-CoV-2 Infection: a Systematic Review and Meta-analysis in the Initial Phase of COVID-19 Pandemic. Obes Surg 2021:1–7. https://doi.org/10.1007/s11695-020-0521-9. Epub ahead of print.
[4] Suresh S, Siddiqui M, Abu Ghامineh M, et al. Association of obesity with illness severity in hospitalized patients with COVID-19: A retrospective cohort study. Obes Res Clin Pract 2021;15:871–83. https://doi.org/10.1016/j.orcp.2021.02.006. Epub ahead of print.

[5] Kornum JB, Nørgaard M, Dethlefsen C, et al. Obesity and risk of subsequent hospitalization with pneumonia. Eur Respir J 2020;56:1330–6.

[6] Kaspersen KA, Pedersen OB, Petersen MS, et al. Obesity and risk of hospitalization with respiratory infection: results from the Danish Blood Donor Study. Epidemiology 2015;26:580–9.

[7] Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev 2020. https://doi.org/10.1111/obr.13034. Apr 13 Epub ahead of print.

[8] Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang China. Infection 2020 Apr 2. https://doi.org/10.1007/s15010-020-01432-5. Epub ahead of print.

[9] Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-1 in Italy. JAMA 2020 Mar 23. https://doi.org/10.1001/jama.2020.4683.

[10] Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol 2020 Apr 2. https://doi.org/10.1038/s41574-020-0353-9. Epub ahead of print.

[11] Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142(7):547–59.

[12] Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-center, randomized controlled trial. Lancet 2021;397(10271):293–304. https://doi.org/10.1016/S0140-6736(20)32649-0.

[13] Capoccia D, Guida A, Coccia F, et al. Weight Regain and Diabetes Evolution After Sleeve Gastrectomy: a Cohort Study with over 5 Years of Follow-Up. Obes Surg 2020;30(3):1046–51. https://doi.org/10.1007/s11695-019-04250-0.

[14] Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273(3):219–34. https://doi.org/10.1016/j.jim.2012.02.

[15] Iannelli A, Bouam S, Schneck AS, et al. The Impact of Previous History of Bariatric Surgery on Outcome of COVID-19. A Nationwide Medico-Administrative French Study. Obes Surg 2021,31(4):1455–63.https://doi.org/10.1007/s11695-020-05120-9.

[16] Marinari GM, Anselmino M, Tascini C, et al. Bariatric and metabolic surgery during COVID-19 outbreak phase 2 in Italy: why, when and how to restart. Surg Obes Relat Dis 2020;16(10):1614–8. https://doi.org/10.1016/j.soard.2020.06.025.

[17] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934. ae.

[18] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453–7.

[19] Gruppo intersocietario Associazione Chirurghi Ospedalieri italiani, Società Italiana di Chirurgia, Società italiana di Chirurgia Oncologica, Società Italiana di Chirurgia Cardiaca e Società Italiana di Neurochirurgia, Società Italiana di Ginecologia e Ostetricia assieme a quella di Società Italiana di Anestesia, Analgesia, Rianimazione e Terapia Intensiva. Marco Cenzato, Paolo De Paolis, Paolo Del Río, et al. Le attività chirurgiche in era Covid: riflessioni e proposte organizzative per un corretto approccio alla fase 2 della pandemia. A cura del tavolo tecnico sulla chirurgia. https://www.sicoweb.it/attivita-chirurgiche-covid.pdf Accessed on 15.03.2020.

[20] Coccolini F, Perrone G, Chiariugi M, et al. Surgery in COVID-19 patients: operational directives. World J Emerg Surg 2020;15(1):25. https://doi.org/10.1186/s13037-020-00307-2.

[21] Raccomandazioni per la sicurezza dei pazienti durante l’emergenza Coronavirus-Italian Network for Safety in Health Care; Accessed on 15.03.2020.

[22] Navarra G, Komaiei I, Currò G, et al. Bariatric surgery and the COVID-19 pandemic: SICOB recommendations on how to perform surgery during the outbreak and when to resume the activities in phase 2 of lockdown. Updates Surg 2020;72(2):259–68. https://doi.org/10.1007/s13304-020-00821-7.

[23] Rubino F, Cohen RV, Mingrone G, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol 2020;8(7):640–8. https://doi.org/10.1016/S2213-8587(20)30157-1.

[24] https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_3-febbraio-2021_appendix.pdf Accessed 03.02.21.

[25] http://covid19.intelworks.io/ Accessed 03.02.21.

[26] Members of the SARS-CoV-2 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on 1st of March 2021. https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-19_1_march_2021.pdf Accessed 01.03.21.

[27] Singhal R, Tahranii AA, Ludwig C, Mahawar Kfor the GENEVA collaborators. Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study. Lancet 2021;9:7–9. https://doi.org/10.1016/S2213-8587(20)30375-2.

[28] Parmar C. Bariatric and Metabolic Surgery Can Prevent People with Obesity from COVID-19 Infection. Obes Surg 2021;31:424–5. https://doi.org/10.1007/s11695-020-04843-3.

[29] Arezzo A, Francis N, Mintz Y, et al. EAES Group of Experts for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic. EAES Recommendations for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic. Surg Endosc 2021;35(1):1–17. https://doi.org/10.1007/s00464-020-08131-0.